

Clerk of the House of Representatives
 Legislative Resource Center
 B-106 Cannon Building
 Washington, DC 20515

Secretary of the Senate
 Office of Public Records
 232 Hart Building
 Washington, DC 20510

RECEIVED
 SECRETARY OF THE SENATE
 PUBLIC RECORDS
 01 FEB 14 1PM 5:30

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

| | | | |
|---|---------------------------|-------------------|----------------------------|
| 1. Registrant Name Glaxo Wellcome, Inc. | | | |
| 2. Address <input type="checkbox"/> Check if different than previously reported 1500 K Street, NW Suite 650 | | | |
| 3. Principal Place of Business (if different from line 2) City: Washington, DC State/Zip (or Country): 20005 | | | |
| 4. Contact Name Janie Kinney | Telephone 202-715-1000 | E-mail (optional) | 5. Senate ID # 16293-12 |
| 7. Client Name <input checked="" type="checkbox"/> Self | | | 6. House ID # 31461000 |


TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

| | |
|---|---|
| <p>12. Lobbying Firms.</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ <small>Income (nearest \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p> | <p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ <u>1,627,000</u> <small>Expenses (nearest \$20,000)</small></p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p> |
|---|---|

Signature: 
 Printed Name and Title: Sarah J. Welsh, Director, Federal Government Relations

Registrant Name Glaxo Wellcome Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

H.R. 434 Africa Growth & Opportunity Act
S. 666 Africa Growth & Opportunity Act


17. House(s) of Congress and Federal agencies contacted Check if None

US House Of Representatives
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) | New |
|-----------------------|---|--------------------------|
| Janie Kinney | | <input type="checkbox"/> |
| Sara Froelich | | <input type="checkbox"/> |
| Sarah J. Walsh | | <input type="checkbox"/> |
| William Schuyler | | <input type="checkbox"/> |
| Elizabeth Beavin York | | <input type="checkbox"/> |
| Kimberly A. Williams | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date February 14, 2001
Printed Name and Title Sarah J. Walsh, Director, Federal Government Relations

Registrant Name Glaxo Wellcome Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues


- S. 578 Health Care Personal Information Nondisclosure Act of 1999
- S. 881 Medical Information Protection Act of 1999
- H.R. 1057, S. 573 Medical Information Privacy & Security Act
- H.R. 2470 Medical Information Protection and Research Enhancement Act
- H.R. 1941 Health Information Privacy Act
- H.R. 216 Access to Quality Care Act
- H.R. 358, S. 6 Patients' Bill of Rights of 1999
- H.R. 4661, S. 1233 Agriculture Appropriations for 2001
- S. 2448 Medical Data Privacy

17. House(s) of Congress and Federal agencies contacted Check if None
 US House Of Representatives
 US Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Positions (if applicable) | New |
|-----------------------|--|--------------------------|
| Janie Kinney | | <input type="checkbox"/> |
| Sara Froelich | | <input type="checkbox"/> |
| Sarah J. Walsh | | <input type="checkbox"/> |
| William Schuyler | | <input type="checkbox"/> |
| Elizabeth Beavin York | | <input type="checkbox"/> |
| Kimberly A. Williams | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date February 14, 2001
 Printed Name and Title Sarah J. Walsh, Director, Federal Government Relations

Registrant Name Glaxo Wellcome Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

- S. 805 To provide asthma treatment services for children
- S. 1650, H.R. 3064 Appropriations for 2001 for Labor & HHS
- S. 2311, H.R. 4807 Ryan White Care Act Amendments of 2000
- H.R. 2840 Children's Asthma Relief Act of 1999
- H.R. 3301 Public Health Service Act
- H.R. 1965 For increased funding for asthma programs


17. House(s) of Congress and Federal agencies contacted Check if None

US House Of Representatives
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) | New |
|-----------------------|---|--------------------------|
| Janie Kinney | | <input type="checkbox"/> |
| Sara Froelich | | <input type="checkbox"/> |
| Sarah J. Walsh | | <input type="checkbox"/> |
| William Schuyler | | <input type="checkbox"/> |
| Elizabeth Beavin York | | <input type="checkbox"/> |
| Kimberly A. Williams | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date February 14, 2001
 Printed Name and Title Sarah J. Walsh, Director, Federal Government Relations

Registrant Name Glaxo Wellcome Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues


- H.R. 664, S. 731 Prescription Drug Fairness for Seniors Act of 1999
- Medicare Drug Benefit Proposals
- H.R. 1090 The Medicare Full Access to Cancer Treatment Act
- S. 1895 Medicare Preservation & Improvement Act
- S. 1480, H.R. 2782 Seniors Prescription Insurance Coverage Equity Act
- H.R. 2012 Medicare Prescription Drug Benefit Act of 1999
- S. 841 Access to Rx Medications in Medicare
- S. 2835 Medicare Rx Drug Discount & Security Act of 2000
- H.R. 4680 Medicare Rx 2000 Act

17. House(s) of Congress and Federal agencies contacted Check if None
 US House Of Representatives
 US Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) | New |
|-----------------------|---|--------------------------|
| Janie Kinney | | <input type="checkbox"/> |
| Sara Froelich | | <input type="checkbox"/> |
| Sarah J. Walsh | | <input type="checkbox"/> |
| William Schuyler | | <input type="checkbox"/> |
| Elizabeth Beavin York | | <input type="checkbox"/> |
| Kimberly A. Williams | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date February 14, 2001
 Printed Name and Title Sarah J. Walsh, Director, Federal Government Relations

Registrant Name Glaxo Wellcome Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific lobbying issues

S. 2462 Prescription Drug Fairness Act

S. 2466 A bill to require USTR to enter negotiations to eliminate price controls

17. House(s) of Congress and Federal agencies contacted
US Senate


Check if None

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) | New |
|-----------------------|---|--------------------------|
| Janie Kinney | | <input type="checkbox"/> |
| Sara Froelich | | <input type="checkbox"/> |
| Sarah J. Walsh | | <input type="checkbox"/> |
| William Schuyler | | <input type="checkbox"/> |
| Elizabeth Beavin York | | <input type="checkbox"/> |
| Kimberly A. Williams | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature  Date February 14, 2001

Printed Name and Title Sarah J. Walsh, Director, Federal Government Relations

Registrant Name Glaxo Wellcome Client Name Self

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City _____ State/Zip (or Country) _____

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

Sara Froelich

ISSUE UPDATE

24. General lobbying issues previously reported that no longer pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

| Name | Address | Principal Place of Business (city and state or country) |
|------|---------|--|
| | | |


26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

| Name | Address | Principal place of business (city and state or country) | Amount of contribution for lobbying activities | Ownership percentage in client |
|------|---------|--|---|--------------------------------------|
| | | | | |

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

Signature  Date February 14, 2001

Printed Name and Title Sarah J. Walsh, Director, Federal Government Relations